Ovensa announced that it has entered into a collaboration agreement with Tetra Bio-Pharma to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.
Advanced Code injection
Ovensa announced that it has entered into a collaboration agreement with Tetra Bio-Pharma to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.